IT202200007229A1 - Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche - Google Patents

Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche Download PDF

Info

Publication number
IT202200007229A1
IT202200007229A1 IT102022000007229A IT202200007229A IT202200007229A1 IT 202200007229 A1 IT202200007229 A1 IT 202200007229A1 IT 102022000007229 A IT102022000007229 A IT 102022000007229A IT 202200007229 A IT202200007229 A IT 202200007229A IT 202200007229 A1 IT202200007229 A1 IT 202200007229A1
Authority
IT
Italy
Prior art keywords
acetylcysteine
vitamin
composition including
nutraceutical compositions
related pharmaceutical
Prior art date
Application number
IT102022000007229A
Other languages
English (en)
Inventor
Lorenzo Secondini
Mietta Catera
Original Assignee
Uriach Italy S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach Italy S R L filed Critical Uriach Italy S R L
Priority to IT102022000007229A priority Critical patent/IT202200007229A1/it
Priority to PCT/IB2023/053745 priority patent/WO2023199244A1/en
Publication of IT202200007229A1 publication Critical patent/IT202200007229A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
IT102022000007229A 2022-04-12 2022-04-12 Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche IT202200007229A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102022000007229A IT202200007229A1 (it) 2022-04-12 2022-04-12 Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
PCT/IB2023/053745 WO2023199244A1 (en) 2022-04-12 2023-04-12 Composition comprising n-acetylcysteine, vitamin d and preferably glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102022000007229A IT202200007229A1 (it) 2022-04-12 2022-04-12 Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche

Publications (1)

Publication Number Publication Date
IT202200007229A1 true IT202200007229A1 (it) 2023-10-12

Family

ID=82385403

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102022000007229A IT202200007229A1 (it) 2022-04-12 2022-04-12 Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche

Country Status (1)

Country Link
IT (1) IT202200007229A1 (it)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029101A1 (en) * 1996-12-31 1998-07-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
US20070116779A1 (en) * 2005-11-23 2007-05-24 Elizabeth Mazzio Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease
JP2010120916A (ja) * 2008-11-22 2010-06-03 Rena Science:Kk 体内生理活性モノアミンの減少に関連して発症する精神・神経疾患の改善または治療剤
US10105419B2 (en) * 2015-02-13 2018-10-23 Eastern Vision Limited Dietary supplements and formulations
WO2020053754A1 (en) 2018-09-10 2020-03-19 Uriach Italia S.R.L. Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
US20200254073A1 (en) * 2017-10-27 2020-08-13 Beyond Barriers Therapeutics, Inc. Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029101A1 (en) * 1996-12-31 1998-07-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
WO2003077900A1 (en) * 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
US20070116779A1 (en) * 2005-11-23 2007-05-24 Elizabeth Mazzio Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease
JP2010120916A (ja) * 2008-11-22 2010-06-03 Rena Science:Kk 体内生理活性モノアミンの減少に関連して発症する精神・神経疾患の改善または治療剤
US10105419B2 (en) * 2015-02-13 2018-10-23 Eastern Vision Limited Dietary supplements and formulations
US20200254073A1 (en) * 2017-10-27 2020-08-13 Beyond Barriers Therapeutics, Inc. Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress
WO2020053754A1 (en) 2018-09-10 2020-03-19 Uriach Italia S.R.L. Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALI AMMAR ET AL: "Vitamin D exerts neuroprotection via SIRT1/nrf-2/ NF-kB signaling pathways against D-galactose-induced memory impairment in adult mice", NEUROCHEMISTRY INTERNATIONAL, ELSEVIER, AMSTERDAM, NL, vol. 142, 4 November 2020 (2020-11-04), XP086431488, ISSN: 0197-0186, [retrieved on 20201104], DOI: 10.1016/J.NEUINT.2020.104893 *
FRANCESCA UBERTI ET AL: "Protective effects of 1 ? ,25-Dihydroxyvitamin D3 on cultured neural cells exposed to catalytic iron", PHYSIOLOGICAL REPORTS, vol. 4, no. 11, 1 June 2016 (2016-06-01), US, pages e12769, XP055586068, ISSN: 2051-817X, DOI: 10.14814/phy2.12769 *
LEMON J A ET AL: "A dietary supplement abolishe age-related cognitive defcline in transgenic mice expressing elevated free radical processes", EXPERIMENTAL BIOLOGY AND MEDICINE, SAGE PUBLICATIONS LTD, GB, vol. 228, 1 January 2003 (2003-01-01), pages 800 - 810, XP002436865, ISSN: 1535-3702 *
MOLINARI CMORSANUTO VGHIRLANDA S ET AL.: "Role of combined Lipoic acid and Vitamin D3 on Astrobytes as a way to prevent Brain aging by induced oxidative stress and Iron accumulation", OXID MED CELI LONGEV, 28 February 2019 (2019-02-28)
ROSS ERIKA K ET AL: "Immunocal and preservation of glutathione as a novel neuroprotective strategy for degenerative disorders of the nervous system", RECENT PATENTS ON CNS DRUG DISCOVERY, BENTHAM SCIENCE PUBLISHERS LTD, NL, vol. 7, no. 3, 30 November 2012 (2012-11-30), pages 230 - 235, XP009501358, ISSN: 2212-3954 *

Similar Documents

Publication Publication Date Title
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
BRPI0608402B8 (pt) compostos de flavonóide e composições compreendendo os mesmos
AR065246A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
AR051397A1 (es) Composicion farmaceutica
AR060387A1 (es) Suplementos alimenticios y sus usos
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
ATE511514T1 (de) Phosphadiazin-hcv-polymerase-hemmer vom typ iv
WO2007036802A3 (en) Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
BR112016010875A8 (pt) Composição útil para a promoção da fertilidade feminina
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
BRPI0814189A2 (pt) Ácido ribonucleico de filamento duplo, composição farmacêutica e seus usos, método para inibir a expressão de fosfatidilinositol 4-cinase, vetor e uso de um composto que seletivamente inibe a atividade da fosfatidilinositol 4-cinase.
NO20054945L (no) Orale formulering av cladribin
ECSP10010167A (es) Composiciones oftálmicas novedosas
DK3519416T3 (da) Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
IT202200007229A1 (it) Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007238A1 (it) Composizione comprendente n-acetilcisteina, vitamina d e preferibilmente glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007226A1 (it) Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche
IT202200007232A1 (it) Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche